Sleep disorders affect millions, spanning conditions like insomnia, restless legs syndrome, and obstructive sleep apnea. Many overlap with mental health and safety risks, from anxiety comorbidity to higher motor vehicle crash risk. This page maps the most common connections and explains how clinicians diagnose and treat sleep problems—using options such as CBT-I, CPAP, home sleep apnea testing, and telehealth-supported care.
Key Takeaways
- 3.1% of US adults reported taking sleep medication in the past month in 2022, indicating ongoing pharmacologic management use
- 30% of people with insomnia also meet criteria for an anxiety disorder, showing frequent comorbidity
- The odds of depression are 2.4 times higher among adults with insomnia than those without insomnia in a meta-analysis
- OSA is associated with a 3.3-fold increased risk of motor vehicle crashes in a meta-analysis
- Sleep apnea is associated with increased risk of motor vehicle crashes; related societal cost estimates are reported in transportation sleep-safety analyses
- $149.6 billion economic cost of insomnia in the US (lost productivity and healthcare burden) estimated for a recent year in a well-cited economic analysis
- $16 billion annual US cost attributed to OSA-related healthcare and productivity losses reported in a cost analysis
- For restless legs syndrome, dopamine agonists or alpha-2-delta ligands are first-line per clinical practice guidance; choice reflects symptom severity and augmentation risk
- Home Sleep Apnea Testing (HSAT) is recommended by clinical guidance as an alternative diagnostic strategy for many patients, reducing time-to-diagnosis
- Continuous Positive Airway Pressure (CPAP) reduces OSA-related severity measured by AHI, with typical reports showing large AHI reductions in clinical trials
- The global sleep apnea devices market is forecast to reach roughly $4.0 billion by 2030 (from a 2020s base), reflecting demand growth
- The global sleep aids market size is reported at $XX (with growth projections) in recent vendor research; sleep aids includes OTC and supplements
- The US sleep disorders testing market is reported to grow with increased demand for diagnostic services, with market research projecting multi-year expansion
- Telehealth delivery of sleep services grew sharply during COVID-19, with a large share of sleep medicine clinics reporting tele-visit use
- Wearables can estimate sleep; validation studies report mean total sleep time errors often within ~30–60 minutes compared with PSG depending on device and algorithms
Insomnia and sleep apnea are widespread and costly, driving higher depression risk, accidents, and billions in annual healthcare use.
Related reading
01 · Category
Global Burden1 stats
01
3.1% of US adults reported taking sleep medication in the past month in 2022, indicating ongoing pharmacologic management use
Interpretation
Global Burden Interpretation
In the Global Burden context, 3.1% of US adults reported taking sleep medication in the past month in 2022, showing a persistent level of ongoing sleep-disorder treatment that implies ongoing health burden rather than a one-time issue.
02 · Category
Comorbidities & Outcomes9 stats
01
30% of people with insomnia also meet criteria for an anxiety disorder, showing frequent comorbidity
02
The odds of depression are 2.4 times higher among adults with insomnia than those without insomnia in a meta-analysis
03
OSA is associated with a 3.3-fold increased risk of motor vehicle crashes in a meta-analysis
04
Obstructive sleep apnea increases risk of cardiovascular disease by about 1.6x in meta-analytic evidence
05
COPD patients have an increased prevalence of insomnia symptoms, with pooled prevalence reported at 45% in a systematic review/meta-analysis
06
RLS is associated with an increased risk of depression; a meta-analysis reports a pooled odds ratio of 1.7
07
Insomnia increases all-cause mortality by 1.2x in meta-analytic evidence
08
Shift workers have a 23% higher risk of developing insomnia compared with day workers in a meta-analysis
09
Adults with insomnia symptoms have a 1.4x higher risk of developing type 2 diabetes reported in meta-analytic evidence
Interpretation
Comorbidities & Outcomes Interpretation
Across comorbidities and outcomes, insomnia and other sleep disorders commonly travel with serious mental and physical health risks, with insomnia showing a 30% anxiety comorbidity rate and doubling depression odds while obstructive sleep apnea raises motor vehicle crash risk 3.3 times and cardiovascular disease risk by about 1.6 times.
03 · Category
Economic Impact & Cost9 stats
01
Sleep apnea is associated with increased risk of motor vehicle crashes; related societal cost estimates are reported in transportation sleep-safety analyses
02
$149.6 billion economic cost of insomnia in the US (lost productivity and healthcare burden) estimated for a recent year in a well-cited economic analysis
03
$16 billion annual US cost attributed to OSA-related healthcare and productivity losses reported in a cost analysis
04
OSA costs the US economy an estimated $12–$14 billion annually in a widely cited estimate (depending on year assumptions)
05
Insomnia is estimated to cost the US economy $63.2 billion in 2011 dollars for direct and indirect costs
06
Obstructive sleep apnea is associated with substantial healthcare expenditures; a claims analysis reports higher costs among diagnosed patients
07
Workplace absenteeism linked to insufficient sleep: workers with short sleep have higher absence days in occupational studies
08
CMS reports millions of Medicare beneficiaries are diagnosed with sleep apnea/related sleep disorders (counts appear in CMS data summaries)
09
In a cost-effectiveness evaluation, CBT-I is estimated to be cost-effective vs pharmacotherapy over time horizons in multiple health-economic studies (reported ICER values)
Interpretation
Economic Impact & Cost Interpretation
Economic studies show sleep disorders impose major, recurring financial burdens, with insomnia alone estimated at $149.6 billion and $63.2 billion in different US analyses and obstructive sleep apnea costing about $12 to $14 billion to $16 billion annually, underscoring why the Economic Impact and Cost category is dominated by large productivity and healthcare losses rather than small, one-off effects.
More related reading
04 · Category
Diagnosis & Care Pathways10 stats
01
For restless legs syndrome, dopamine agonists or alpha-2-delta ligands are first-line per clinical practice guidance; choice reflects symptom severity and augmentation risk
02
Home Sleep Apnea Testing (HSAT) is recommended by clinical guidance as an alternative diagnostic strategy for many patients, reducing time-to-diagnosis
03
Continuous Positive Airway Pressure (CPAP) reduces OSA-related severity measured by AHI, with typical reports showing large AHI reductions in clinical trials
04
CBT-I shows clinically meaningful reductions in insomnia severity scores by around 50% in randomized trials (reported as mean improvements across studies)
05
Weight loss of 10% in people with OSA is associated with improved AHI in clinical evidence, informing treatment escalation
06
Oral appliance therapy reduces AHI in mild-to-moderate OSA; meta-analysis evidence reports significant AHI reductions versus baseline
07
AASM recommends that PAP adherence is monitored, with adherence often defined in studies/clinical programs as ≥4 hours per night on ≥70% of nights
08
50% average reduction in insomnia severity with CBT-I (percent improvement vs baseline across trials)
09
36% average reduction in insomnia severity with pharmacotherapy vs baseline (percent improvement vs baseline across trials)
10
50% average reduction in insomnia severity with combined behavioral strategies vs baseline (percent improvement vs baseline across trials)
Interpretation
Diagnosis & Care Pathways Interpretation
Across Diagnosis and Care Pathways, clinical guidance and trials consistently support earlier and targeted interventions that can cut severity meaningfully, including about a 50% mean reduction in insomnia severity with CBT-I and large AHI drops with CPAP and other step up options like weight loss of around 10% and oral appliances.
report visual · Comparison
Insomnia severity reduction: CBT-I vs pharmacotherapy vs combined behavioral strategies
Across global adult insomnia trials, CBT-I shows the strongest direction of improvement (leader) with a ~50% average reduction in insomnia severity vs ~36% for pharmacotherapy, cre
50% average reduction in insomnia severity with CBT-I (percent improvement vs baseline across trials)50%
50% average reduction in insomnia severity with combined behavioral strategies vs baseline (percent improvement vs basel
50%
36% average reduction in insomnia severity with pharmacotherapy vs baseline (percent improvement vs baseline across tria
36%
source-verifiedpubmed.ncbi.nlm.nih.gov2011
05 · Category
Market Size & Growth8 stats
01
The global sleep apnea devices market is forecast to reach roughly $4.0 billion by 2030 (from a 2020s base), reflecting demand growth
02
The global sleep aids market size is reported at $XX (with growth projections) in recent vendor research; sleep aids includes OTC and supplements
03
The US sleep disorders testing market is reported to grow with increased demand for diagnostic services, with market research projecting multi-year expansion
04
The global neuromodulation market for sleep-related disorders is forecast to expand over the 2020s, reflecting adoption of advanced therapies
05
The US home sleep testing market is forecast to grow rapidly through 2030 in market research due to shift to at-home diagnostics
06
The global polysomnography market is projected to grow through 2030 due to diagnostic demand and wearable-screening adoption
07
The global sleep medicine market is forecast to reach about $X billion by 2030 in market research aggregations
08
The US sleep disorders treatment market is projected to expand through the late 2020s in vendor reports, reflecting increased diagnoses
Interpretation
Market Size & Growth Interpretation
The market for sleep-related solutions is expanding fast, with the global sleep apnea devices market projected to reach about $4.0 billion by 2030, signaling sustained growth across the broader sleep disorder Market Size and Growth landscape.
06 · Category
Industry Trends & Adoption7 stats
01
Telehealth delivery of sleep services grew sharply during COVID-19, with a large share of sleep medicine clinics reporting tele-visit use
02
Wearables can estimate sleep; validation studies report mean total sleep time errors often within ~30–60 minutes compared with PSG depending on device and algorithms
03
CPAP adherence monitoring via remote data is increasingly used; studies report that telemonitoring improves adherence rates
04
Treatment for insomnia includes behavioral therapy and digital CBT-I; randomized trials show remote CBT-I can reduce insomnia severity
05
Mandibular advancement devices are widely prescribed for mild-to-moderate OSA; real-world claims analyses report meaningful penetration in specialty markets
06
Sleep clinics increasingly incorporate actigraphy; clinical research reports diagnostic utility of actigraphy for certain circadian rhythm disorders
07
Insomnia and sleep disturbance recognition is rising in health systems; claims-based analyses report increased diagnosis codes over time
Interpretation
Industry Trends & Adoption Interpretation
Industry adoption of sleep care is accelerating, with major upticks in telehealth during COVID-19, wearables showing total sleep time errors often only around 30 to 60 minutes versus PSG, and remote CPAP telemonitoring and CBT-I increasingly proving their value in improving adherence and reducing insomnia severity.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Sleep Disorder Statistics. Gitnux. https://gitnux.org/sleep-disorder-statistics
MLA
Gabrielle Fontaine. "Sleep Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sleep-disorder-statistics.
Chicago
Gabrielle Fontaine. 2026. "Sleep Disorder Statistics." Gitnux. https://gitnux.org/sleep-disorder-statistics.
Sources & references
44 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)